Related Experiment Videos
Spironolactone therapy in infants with congestive heart failure secondary to congenital heart disease
Insights
Spironolactone significantly improved treatment response in infants with congenital heart failure. This medication addition enhanced standard therapies, reducing liver size and respiratory rate more effectively.
Area of Science:
- Pediatrics
- Cardiology
- Pharmacology
Background:
- Congestive heart failure (CHF) in infants with congenital heart disease (CHD) presents significant management challenges.
- Standard treatments include digoxin and chlorothiazide, but further optimization is often needed.
Purpose of the Study:
- To evaluate the efficacy of spironolactone as an adjunct therapy for CHF secondary to CHD in infants.
- To compare the effects of spironolactone versus potassium supplementation in infants with CHF.
Main Methods:
- A study involving 21 infants under 1 year of age with CHF secondary to CHD.
- Infants received standard treatment with digoxin and chlorothiazide.
- Group A (n=10) received potassium supplements, while Group B (n=11) received spironolactone.
Main Results:
- Group B (spironolactone) showed significant reductions in liver size and weight (P<0.01) and respiratory rate (P<0.05).
- Group A showed less significant decreases in these parameters.
- Spironolactone group exhibited a slightly lower incidence of vomiting.
Conclusions:
- Spironolactone addition hastens and enhances the response to standard treatment (digoxin and chlorothiazide) in infants with CHF.
- Spironolactone appears to be a beneficial adjunct therapy for pediatric CHF.
- Further research may explore optimal dosing and long-term effects.
Abstract:
The efficacy of treatment with spironolactone for congestive heart failure secondary to congenital heart disease was studied in 21 infants under 1 year of age. All received digoxin and chlorothiazide. In addition, group A (n = 10) was given supplements of potassium and group B (n = 11) received spironolactone. Daily clinical observations of vital signs, weight, hepatomegaly, and vomiting were recorded. Paired t test analysis showed significant reduction in liver size and weight (P less than 0.01) and respiratory rate (P less than 0.05) in group B, and less significant decreases in group A. The incidence of vomiting was slightly lower in group B. We conclude that the addition of spironolactone hastens and enhances the response to standard treatment with digoxin and chlorothiazide in infants with congestive heart failure.